Business Context and Reporting Period
Company: Incyte Genomics, Inc. (formerly Incyte Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2001
Business Overview: Incyte designs, develops, and markets genomic information-based products, including database products, microarray-based gene expression services, and SNP discovery services. The company also engages in internal disease pathway and therapeutic drug discovery programs.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 |
|---|---|---|---|
| Revenues | $57,319 | $164,491 | $138,751 |
| Net Loss | $(17,827) | $(38,030) | $(22,365) |
| Loss per Share (Basic/Diluted) | $(0.27) | $(0.58) | $(0.36) |
| Operating Cash Flow | N/A | $(37,698) | $(5,726) |
| Cash and Cash Equivalents | $45,488 | $45,488 | $32,220 (Beginning of 2001) |
| Marketable Securities | $472,058 | $472,058 | $472,025 (Dec 31, 2000) |
| Total Debt (Convertible Notes) | $179,358 | $179,358 | $187,814 (Dec 31, 2000) |
| Accumulated Deficit | $(122,935) | $(122,935) | $(84,904) (Dec 31, 2000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10.3% for the quarter and 18.5% for the nine-month period compared to 2000, driven by expanded customer base and database access fees.
- Increased Losses: Net loss widened significantly to $38.0 million for the nine months ended September 30, 2001, compared to $22.4 million in the prior year. This was driven by higher operating expenses and specific charges.
- Restructuring Charges: The company recorded a $5.8 million loss on the sale of assets related to the divestiture of its transgenics product line in Q3 2001.
- Investment Impairments: A $9.0 million impairment charge on long-term strategic investments was recorded in the first nine months of 2001, reducing interest and other income.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose due to litigation costs (approximately $10.7 million for the nine months) and sales force expansion. R&D expenses increased due to bioinformatics efforts and goodwill amortization from the Proteome acquisition.
- Cash Position: Cash and cash equivalents decreased from $110.2 million at year-end 2000 to $45.5 million at September 30, 2001, primarily due to operating cash outflows and capital expenditures.
Guidance, Outlook, and Risks
Restructuring and Future Charges
On October 25, 2001, Incyte announced a major restructuring to focus on database/partnership operations and internal drug discovery. The company plans to discontinue microarray-based gene expression services, genomic screening, and contract sequencing. This includes closing facilities in Fremont, CA, and St. Louis, MO, and reducing the workforce by approximately 400 employees.
Financial Impact: Management expects to recognize an additional non-recurring charge in the fourth quarter of 2001 that could exceed $80 million. Approximately 25% of this charge is anticipated to be cash-related, with the remainder associated with asset write-offs.
Litigation Risks
- Affymetrix: Ongoing patent infringement lawsuits filed by Affymetrix in 1998 and 2000. While Incyte secured summary judgments invalidating certain Affymetrix patent claims in late 2001, the litigation continues with counterclaims. The company cannot estimate potential losses but notes substantial legal expenses and management distraction.
- Invitrogen: A new lawsuit filed in October 2001 alleging infringement of three patents related to reverse transcriptase. Incyte intends to defend vigorously.
Outlook
The company expects to report a net loss for the full year 2001. It anticipates continuing significant investments in its intellectual property portfolio and therapeutic drug discovery programs. Management believes existing resources are adequate to satisfy capital needs for at least the next twelve months.
Investor Verification Checklist
- Q4 Restructuring Charge: Verify the final magnitude of the anticipated >$80 million non-recurring charge and the specific cash impact (approx. 25%).
- Litigation Status: Monitor the status of the Affymetrix counterclaims and the new Invitrogen lawsuit for potential injunctions or damages.
- Revenue Sustainability: Assess the impact of discontinuing microarray and sequencing services on future revenue streams and customer retention.
- Cash Burn Rate: Review the trajectory of operating cash burn ($37.7M used in 9 months) against the remaining cash balance ($45.5M) and marketable securities ($472M).
- Debt Obligations: Confirm the status of the $179.4 million convertible subordinated notes due in 2007 and any potential conversion or redemption triggers.